BLU News and Press, BELLUS Health Inc. From 12/13/21

Shares of Bellus Health (NASDAQ: BLU) , a clinical-stage biotechnology company, are soaring in response to positive clinical-trial data. Investors excited about the company's lead candidate BLU-5937 drove the stock 58.4% higher as of 10:30 a.m. ET on Monday. Bellus Health's lead...

Gainers: Arena Pharmaceuticals (NASDAQ:ARNA) +84%, BELLUS Health (NASDAQ:BLU) +68%, Foghorn Therapeutics (NASDAQ:FHTX) +37%, Petros Pharmaceuticals (NASDAQ:PTPI) +27%, Tabula Rasa HealthCare (NASDAQ:TRHC) +23%. Losers: IGM Biosciences (NASDAQ:IGMS)...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nuverra Environmental (NYSEAMERICAN: NES ) stock is surging higher on Monday following news of a massive deal with Select Energy Services (NYSE: WTTR ). Source: Shutterstock.com This deal will have Selec...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips BELLUS Health (NASDAQ: BLU ) stock is rocketing higher on Monday and it’s all thanks to data from a Phase 2b clinical trial. Source: Shutterstock This clinical trial saw it testing the effectiveness of ...

Biotech Penny Stocks To Watch Right Now Penny stocks are some of the most exciting things to trade if you’re looking to make money quickly. There aren’t many ways to double or triple a small investment in less than 12 months. Despite these cheap stocks coming with higher r...

Arena Pharmaceuticals (NASDAQ:ARNA) +90% on acquisition by Pfizer. Foghorn Therapeutics (NASDAQ:FHTX) +38% after collaborating with Lilly in oncology medicines. BELLUS Health (NASDAQ:BLU) +36% on positive BLU-5937 data in mid-stage chronic cough study. Petros Pha...

Bellus Health (NASDAQ:BLU) soars 33% premarket after announcing that the 50 mg and 200 mg BID doses of BLU-5937 in its Phase 2b SOOTHE trial for the treatment of refractory chronic cough (RCC) achieved statistical significance on the primary endpoint with 34% placebo-...

Primary efficacy endpoint statistically significant with 34% placebo-adjusted reduction in 24-hour cough frequency observed at 50 mg and 200 mg BID doses (p ≤ 0.005) BLU-5937 was well-tolerated with a low rate of taste-related adverse events ( ≤ 6.5%); treatm...

Gainers: Cumberland Pharmaceuticals  (NASDAQ:CPIX) +111%. Adagene (NASDAQ:ADAG) +12%. PLAYSTUDIOS (NASDAQ:MYPS) +7%. Verastem (NASDAQ:VSTM) +6%. Chimerix CMRX +6%. Losers: BELLUS Health  (NASDAQ:BLU) -7%. LIZHI  (NASDAQ:LIZI) -6%. NRX Pharmaceuticals (NASDAQ:NRXP...

Gainers Cumberland Pharmaceuticals  (NASDAQ:CPIX) +111%. Adagene  (NASDAQ:ADAG) +12%. PLAYSTUDIOS (NASDAQ:MYPS) +7%. Verastem (NASDAQ:VSTM) +6%. Chimerix (NASDAQ:CMRX) +6%. Losers: BELLUS Health  (NASDAQ:BLU) -7%. LIZHI  (NASDAQ:LIZI) -6%. NRX Pharmaceuticals (NA...